Sjögren’s Syndrome Therapeutics - Clinical Trials, Designation and Developments
The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis
The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren's syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.
Anesthesia Monitoring Device Market - Analysis, Size and Demand, 2023
The global anesthesia monitoring device market is witnessing substantial growth due to advancement in technology of anesthesia monitoring device and increasing number of surgeries. Growing awareness among physicians about various factors such as appropriate route of administration, right dose of anesthetic drug and choice of anesthetic drug, is further expected to boost the market. Based on product type, advanced anesthesia monitor was globally the largest segment due to its accuracy, durability and reliability in monitoring anesthesia. It also helps in monitoring vital parameters such as oxygen saturation level, heart rate, blood pressure, and carbon dioxide levels. Hospitals have been the largest user of anesthesia monitoring devices due to availability of advanced healthcare infrastructure, and presence of skilled professionals in the hospital.
Explore Report at: https://www.psmarketresearch.com/market-analysis/anesthesia-monitoring-device-market
Rapidly growing geriatric population is also expected to be a growth factor for the anesthesia monitoring device market, as geriatric population has weakened body functions and require proper monitoring during the surgery. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with high rate. The global percentage of people aged 60 or above in 2013 was 11.7% and it is expected to reach 21.1% by the end of 2050. Further, the number of people aged 60 years and above is expected to reach approximately 437 million in China, 324 million in India, 107 million in the U.S. and 58 million in Brazil by 2050.
The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest market for anesthesia monitoring device, owing to increasing awareness of patient safety and awareness among patient and physicians, favorable reimbursement network, and favorable government funding in the region. The U.S. contributed largest revenue to the North American as well as global anesthesia monitoring device market. Globally, the anesthesia monitoring device market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to growing geriatric population, large pool of patients, advancing healthcare system, and increasing number of surgeries in the region.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/anesthesia-monitoring-device-market/report-sample
The key players operating in the global market are Medtronic Plc, General Electric Company, Philips Healthcare, Masimo Corporation, Nihon Kohden Corporation, Dragerwerk AG & Co. KGaA, Schiller AG and Mindray Medical International Limited.
E-Prescribing Market - Research Report, Analysis, Demand, 2023
E-Prescribing system facilities the practitioner to generate a new prescription electronically whenever treatment error occurs during healthcare operations. E-Prescribing system offers extensive range of applications. It provides comprehensive form of medical data, ensures all security checks and patents identification. It offers completest privacy to the disease information and patient’s identification with present and historical data.
Explore more “E-Prescribing Market” at: https://www.psmarketresearch.com/market-analysis/e-prescribing-market
Based on the different product type the global e-prescribing market can be broadly classified as, stand-alone systems, and integrated systems. Based on the different components of electronics prescribing the global e-prescribing market can be segmented as software and hardware (including access devices, peripherals, servers, storage devices, and networking devices) and services (including consulting, implementation services, post-sale & maintenance and training services). On the bases of mode of the delivery of the e-prescription the global e-prescription market can be classified as on premise, web-based and cloud. Further, based on the end user application the market can be segmented as hospitals and office-based physicians.
The global e- prescription market is predominantly driven by the increasing adoption of e-prescription in healthcare systems. It offers cost benefits over the conventional prescription market in longer run while ensuring quality healthcare services to patients at minimized treatments and adverse drug errors. Moreover the various government initiatives such as American Recovery and Reinvestment Act (ARRA) in 2009 for the advancement of the Healthcare IT, and HITECH Act is driving the demand of e-Prescribing systems in North America.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/e-prescribing-market/report-sample
Major Competitors: The global e-prescription market is dominated by Bioclinica, Inc., Bizmatics Inc., CRF Health, DATARAK International, Inc., eResearch Technology, Inc., Some of the top competitors in the global clinical trial management system market are e-MDs, Inc., iMedX, Inc., Practice Fusion, Inc., SureScripts-RxHub, LLC, eClinicalWorks, LLC, and Quality System, Inc.
Active Pharmaceutical Ingredients Market - Global Industry Insight, Size, Growth, 2023
The global active pharmaceutical ingredient market is growing significantly due to patent expiry of biologic drugs in the industry. Patent expiry of blockbuster drugs has boosted the demand for low cost substitutes, which further increases the demand for active pharmaceutical ingredients in the industry. Moreover, increasing investment into biosimilars is expected to support the growth of the market in the coming years.
Explore Report at: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredients-market
Massive unexplored market in active pharmaceutical ingredient industry of developing economies are creating ample opportunities for the active pharmaceutical ingredient market to grow at a considerable rate in the coming years. Active pharmaceutical ingredients are the primary components of manufacturing effective and safe essential drugs. The advanced research and development facilities of the companies are supporting to address the demand of the active pharmaceutical ingredient industry.
The active pharmaceutical ingredient market can be categorized on the basis of therapeutic areas as oncology drugs, central nervous system drugs, anti-diabetic drugs, musculoskeletal drugs, cardiovascular drugs, and non-steroidal anti-inflammatory drugs. The oncology drugs is expected to grow with the fastest rate in the coming years due to increasing prevalence of cancer cases and rising government initiatives to create awareness about cancer among population.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredients-market/report-sample
Geographically, North America will be leading the global active pharmaceutical ingredient market in the coming years due to increasing research and development programs in the field of drugs and medical science. Asia-Pacific is the fastest growing region in the global active pharmaceutical ingredient market. The major reasons for the fastest growth of the market in the region are increasing healthcare expenditure, large pool of patients, and presence of large pool of generic medicine producers in the region. Moreover, the active pharmaceutical ingredient market is growing due to increasing awareness of lifestyle associated diseses in the emerging countries, such as India and China, of Asia-Pacific region.
Some of the companies operating in the active pharmaceutical ingredient market are Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Actavis Plc, Hospira Inc., Boehringer Ingelheim Group, Lonza Group, Cambrex Corporation, Novartis International AG, BASF SE, Pfizer, Inc., Mylan, Inc., Watson Pharmaceutical Inc., and WuXi Apptec.
Biosimulation Technology Market - Research Report, Analysis & Demand, 2023
The global biosimulation market is growing significantly due to technological advancements and increasing research and development investment in the pharmaceutical and biotechnology industries. Low success rate of drug approval and emerging software applications of biosimulation technology are creating ample opportunities for the global biosimulation technology market to grow at a significant rate in the forecasted period.The advanced research and development facilities and new product developments by the companies are propelling the demand for cost effective biosimulation software.
Explore Report at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market
In biosimulation industry, there is a trend of collaboration and partnership of universities and research institutes with suppliers. Drug discovery and development process is stringent, time consuming, and expensive process. In addition, the success rate of drug approval is very low. According to Tufts Centre for the Study of Drug Development, an academic, non-profit research group at Tufts University, in the U.S., out of 1,000 compounds tested only one makes it to human clinical trials, and out of five such compounds only one gets approved. Biosimulation technology overcomes these limitations by simulating biological systems through software models and increasing predictability in early stages of drug development; hence, saving time and money in drug development process.
Geographically, North America will be leading the global biosimulation technology market in the coming years due to technological advancements, growth in biosimilars and biologics market, high healthcare expenditure, and presence of a large number of pharmaceuticals and biotechnology companies. In addition, the U.S. Food and Drug Administration (FDA), strongly recommends simulation process in drug discovery and development; hence, fueling the growth of biosimulation technology market in North America. Europe is the fastest growing region in the global biosimulation technology market. The major reasons for the fastest growth in the region are high healthcare expenditure and increasing research and development activities.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/biosimulation-technology-market/report-sample
Some of the major players operating in the global biosimulation technology market Dassault Systemes SA, Simulation Plus Inc., Certara USA, Inc., Advanced Chemistry Development, Inc., In Silico Biosciences, Inc., Chemical Computing Group, Inc., Physiomics PLC., Rhenovia Pharma Ltd., Genedata AG, Entelos Holding Corporation, Leadscope, Inc., and Schrodinger Inc. among others.
Mental Health Software Market - Trends, Development and Forecast to 2023
The global mental health software market is growing significantly, due to high potential of subscription model. During the forecast period, the providers segment is expected to hold the largest share, among all the end user segments of the global mental health software market, due to its extensive use for maintaining patient records and management revenue cycle. However, the residential segment is expected to grow with the highest rate during the forecasted period, due to increasing use of behavioral/ mental health solution by patients in their homes for better self-care. Among the various delivery models of mental health software, the subscription model segment is expected to grow with the faster rate, as it is user friendly and cost effective. Moreover, the support services led the component segment of the market, due to recurring requirement of these services for software up-gradation and management.
Explore Report at: https://www.psmarketresearch.com/market-analysis/mental-health-software-market
The unexplored market in the mental health software industry of the developing economies is creating growth opportunities for the mental health software market. Some of the major trends in the global market are growing product innovation, increasing number of collaborations and partnerships, and increasing number of mergers and acquisitions. The mental health software helps behavioral health professionals to plan treatment for patients suffering from mental problems, such as depression, addiction, stress and anxiety. The software helps user to facilitate medical bills and schedule online appointments.
Request for Sample at: https://www.psmarketresearch.com/market-analysis/mental-health-software-market/report-sample
Some of the companies operating in the global mental health software market are Epic Systems Corporation, Quality Systems Inc., Cerner Corporation, Mindlinc, The Echo Group, Netsmart Technologies Inc., Qualifacts Systems Inc., Credible Behavioral Health, Core Solutions Inc., Welligents Inc., and Valant Medical Solutions.
Patient Engagement Solutions Market - Global Industry Insights, Analysis, Forecast to 2023
The global patient engagement solutions market is growing considerably, due to growing medical tourism and increasing cloud based models. During the forecast period, the software segment is expected to report the largest share, among all the components segments of the patient engagement solution market. Among the various delivery modes, the web based delivery segment leads the market, as it is cost effective and user friendly; however, the cloud based delivery segment is expected to grow with the fastest rate during the forecasted period. Among the various applications, the health management segment leads the global patient engagement solutions market. Based on therapeutics area, the chronic diseases segment leads the market in terms of size and is expected to grow with the fastest rate during the forecast period. Among the various end users, the providers segment led the market in 2014.
Explore Report at: https://www.psmarketresearch.com/market-analysis/patient-engagement-solutions-market
The unexplored market in the patient engagement solution industry of the developing economies is creating growth opportunities for the market players. Some of the major trends in the global market are awareness among patients about the solutions, increasing number of mergers and acquisitions, and increasing number of collaborations and partnerships. The patient engagement solutions provide various benefits, such as reduction in hospital readmission rates, cost reduction, improved quality of healthcare, and increased patient outreach.
Geographically, North America is expected to dominate the global market in the coming years, due to growing geriatric population, implementation of Affordable Care Act, and increasing prevalence of chronic diseases. Asia is expected to be the fastest growing region, due to growing medical tourism and increasing healthcare awareness in the region. In addition, the Asian market of patient engagement solutions is growing due to increasing healthcare expenditure and increasing healthcare information technology adoption in the emerging countries, such as India and China.
Ask for TOC at: https://www.psmarketresearch.com/market-analysis/patient-engagement-solutions-market/toc-sample
Some of the companies operating in the global patient engagement solutions market are Mckesson Corporation, Athenahealth Inc., Medecision Inc., Cerner Corporation, Orion Health, Aetna Inc., Emmi Solutions LLC., Allscripts Healthcare Solutions Inc., Getwellnetwork Inc., and Phytel Inc.
